Neutrophil‐Based Delivery Systems for Nanotherapeutics,Small

当前位置： X-MOL 学术 › Small › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Neutrophil‐Based Delivery Systems for Nanotherapeutics
Small ( IF 13.0 ) Pub Date : 2018-08-24 , DOI: 10.1002/smll.201801674
Yu Han ₁ , Ruibo Zhao ₂ , Feng Xu ₁

Affiliation

Neutrophils, the most abundant leukocytes (50–70% of the total leukocytes in circulation), are the major type of cells recruited to sites of inflammation during infection and tumorigenesis, suggesting that neutrophils could contribute to nanotherapeutics for inflammation and cancer therapy. Neutrophil‐based delivery has shown great potential in circumventing nanotherapeutics limitations, such as low biocompatibility, short circulation time, and immunogenicity of nanomaterials. In this review, the current development of neutrophil‐based nanotherapeutic drugs in the treatment of inflammatory diseases and cancers is summarized. These successful neutrophil‐based nanotherapeutic systems indicate that introducing functional nanomaterials into neutrophils and neutrophil‐based vesicles may be a promising strategy for improving the nanotherapeutics in more complex conditions. The integration between neutrophils and nanomaterials will create more opportunities for future materials and medical studies.

中文翻译：

基于中性粒细胞的纳米治疗给药系统

中性粒细胞是最丰富的白细胞（占循环中白细胞总数的50-70％），是在感染和肿瘤发生期间募集到炎症部位的主要细胞类型，这表明中性粒细胞可以为炎症和癌症治疗的纳米疗法做出贡献。基于中性粒细胞的递送在克服纳米疗法的局限性方面表现出巨大潜力，例如生物相容性低，循环时间短和纳米材料的免疫原性。在这篇综述中，总结了基于中性粒细胞的纳米治疗药物在炎性疾病和癌症治疗中的最新发展。这些成功的基于中性粒细胞的纳米治疗系统表明，将功能性纳米材料引入中性粒细胞和基于中性粒细胞的囊泡可能是在更复杂条件下改善纳米治疗剂的一种有前途的策略。中性粒细胞和纳米材料之间的整合将为未来的材料和医学研究创造更多的机会。

更新日期：2018-08-24

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11